Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI

International Journal of Cardiology

Volumn 108, Issue 3, 2006, Pages 314-319

  Wright, R Scott ^a,b,e   Bybee, Kevin ^a   Miller, Wayne L ^a,b   Laudon, Dennis A ^c   Murphy, Joseph G ^a,b   Jaffe, Allan S ^a,b,d  

^a Division of Cardiology   (United States)

^b UVA Health   (United States)

^c Department of Emergency Medicine ^*  (United States)

^d MAYO CLINIC   (United States)

^e Mayo Clinic   (United States)

Author keywords

Acute myocardial infarction; CHF; Statin theraphy

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRATE; PRAVASTATIN; SIMVASTATIN;

ACUTE DRUG ADMINISTRATION; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CREATINE KINASE; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK; TIME FACTORS;

EID: 33644764024     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.05.014     Document Type: Article

References (27)

1. K. Bybee, R.S. Wright, B. Williams, J. Murphy, D. Holmes, and S. Kopecky Effect of concomitant or very early statin administration on in-hospital mortality and re-infarction rates in patients with acute myocardial infarction Am J Cardiol 87 2001 771 774
2. R. Schiefe, A.K. Gitt, T. Heer, H. Wienbergen, U. Giesler, and H.G. Glunz Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of the Mitra-2 Circulation 102 2000 II-435
3. G.C. Fonarow, R.S. Wright, F. Spencer, P. Frederick, W. Dong, and N. Every for the National Registry of Myocardial Infarction IV Investigators. Statin use within the first 24 hours of admission for AMI is associated with a reduction in early morbidity and mortality Circulation 106 Suppl. II 2002 (November) II-400
4. U. Stenestrand, L. Wallentin for the Swedish Registry of Cardiac Intensive Care Early statin treatment following acute myocardial infarction and 1-year survival JAMA 285 2001 430 436
5. K.A. Bybee, R.S. Wright, B.D. Powell, B.A. Williams, J.T. Vinar, and S.L. Kopecky Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared to ST elevation MI Circulation 102 18 Suppl. 2000 (October) II.614
6. H.D. Aronow, E.J. Topol, M.T. Roe, P.L. Houghtaling, K.E. Wolski, and A.M. Lincoff Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study Lancet 357 2001 1063 1068
7. R.P. Giugliano, E.M. Antman, S.L. Thompson, C.H. McCabe, and E. Braunwald Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower post-discharge 1-year mortality J Am Coll Cardiol 2001 316A
8. C.P. Cannon, C.H. McCabe, J. Bentley, and E. Braunwald Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 J Am Coll Cardiol 2001 334A
9. M. Kayikcioglu, C. Turkoglu, H. Kultursay, H. Evrengul, and L. Can The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction Circulation 100 1999 I-303
10. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, and D. Waters Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study JAMA 285 13 2001 1711 1718
11. Van Boven AJ, Liem A. Effects of fluvastatin administration immediately after an acute myocardial infarction on myocardial ischemia (FLORIDA). Oral presentation, American Heart Association Scientific Session 2000; New Orleans, LA: Nov 12-15, 2000.
12. H. Arntz, W. Wunderlich, L. Schnitzer, R. Stern, F. Fischer, and R. Agrawal Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study Z Kardiol 88 8 1999 582 590
13. Hotline Presentation of the Princess Trial. European Society of Cardiology 2004 Scientific Meeting. www.escardio.org.
14. P.L. Thompson, I. Meredith, and J. Amerena Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial Am Heart J 148 1 2004 (July) e2
15. Anonymous Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults(ATP-III) JAMA 285 19 2001 2486 2497
16. R.S. Wright, J.G. Murphy, K.A. Bybee, S.L. Kopecky, and J.M. LaBlanche Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit Mayo Clin Proc 77 2002 1085 1092
17. G.C. Fonarow, W.J. French, L.S. Parsons, H. Sun, and J.A. Malingren Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3 Circulation 103 1 2001 38 44
18. J. Herrmann, A. Lerman, D. Baumgart, L. Volbracht, R. Schulz, and C. von Birgelen Pre-procedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction Circulation 106 17 2002 2180 2183
19. K.A. Bybee, S.L. Kopecky, B.A. Wiliams, J.G. Murphy, and R.S. Wright Reduced creatine kinase release with statin use at the time of myocardial infarction Int J Cardiol 96 2004 461 466
20. S.P. Jones, and D.J. Lefer Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction Acta Physiol Scand 173 2001 139 143
21. C.P. Tiefenbacher, J. Kapitza, V. Dietz, C.-H. Lee, and F. Niroomand Reduction of myocardial infarct size by fluvastatin Am J Physiol Heart Circ Physiol 285 2003 H59 H64
22. R.F. Gillum, S.P. Fortmann, R.J. Prineas, and T.E. Kottke WHO criteria for diagnosis of acute myocardial infarction Am Heart J 108 1984 150 158
23. M.B. Harris, M.A. Blackstone, S.G. Sood, C. Li, J.M. Goolsby, and V.J. Venema Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors Am J Physiol Heart Circ Physiol 287 2004 H560 H566
24. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors Arterioscler Thromb Vasc Biol 21 2001 1712 1719
25. P.M. Ridker for the Cholesterol and Recurrent Events (CARE) Investigators Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels Circulation 98 1998 839 844
26. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 Investigators N Engl J Med 350 2005 1495 1504
27. M. Kayikcioglu, L. Can, H. Kultursay, S. Payzin, and C. Turkoglu Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty Acta Cardiol 57 2002 295 302